A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma

Trial Details

NCT ID
NCT06194734
Phase
PHASE3
Sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • KC1036
  • Irinotecan
  • Docetaxel
  • S-1
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Males or females aged 18 to 75 years;
  • Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma;
  • Patient with advanced recurrent or metastatic esophageal squamous cell carcinoma previously treated with a PD-1 or PD-L1 inhibitor and at least sec…
  • At least one measurable tumor lesion according to RECIST 1.1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →